-
Published 6/16/2026
Ryan DH, Fitch A, Kushner RF, Tronieri JS, Still CD, Apovian CM. Identifying Predictors of Weight-Related Outcomes With Fixed-Dose, Extended-Release Naltrexone and Bupropion Among Treatment-Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis. Obes Sci Pract. 2026 Jun; 12(3):e70159. PMID: 42311561.
-
Published 6/3/2026
Baer HJ, Cho J, Fay R, Apovian CM, McCarthy AC, Blood AJ, Samal L, Fisher NDL, Orav EJ, Wien M, Plutzky J, Block JP, Bates DW, Rozenblum R, Tucci M, McPartlin M, Oates M, McManus KD, Scirica BM. Engagement and Weight Change in an Online Weight Management Program in Clinical Settings: An Implementation Project. J Gen Intern Med. 2026 Jun 03. PMID: 42234371.
-
Published 5/9/2026
Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M, Gupta A, Horn D, Kane RM, Saluja J, Sanndhi D, Stanford FC, Callahan EA. Erratum: Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obes Pillars. 2026 Jun; 18:100269. PMID: 42255462.
-
Published 4/2/2026
Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M, Gupta A, Horn D, Kane RM, Saluja J, Sanndhi D, Stanford FC, Callahan EA. Corrigendum to "Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society [Obesity Pillars 15 (2025) 100181]. Obes Pillars. 2026 Jun; 18:100263. PMID: 42255463.
-
Published 3/31/2026
Tronieri JS, Kushner RF, Apovian CM, Fitch A, Still C, Wadden TA. Use of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis. Obesity (Silver Spring). 2026 May; 34(5):1010-1019. PMID: 41914839.